The aim of the study was to determine whether an oral treatment with a commercial pharmaceutical product containing Saccharomyces boulardii would reduce the duration of diarrhea in infants with acute diarrhea.
In the present double-blind, placebo-controlled study, 186 infants, 6 to 48 months old and hospitalized within 72 hours after the onset of acute diarrhea in 2 hospitals in Goiânia, Goiás, Brazil, were randomly assigned to receive twice per day for 5 days 200 mg of a commercial pharmaceutical product containing 4 × 109 viable cells of S boulardii or a placebo. Stool samples were submitted to search for rotavirus. Among the 176 infants who completed the trial, those treated with S boulardii (90) showed a reduction in diarrhea duration (P < 0.05) when compared with the placebo group (86).
The present study shows a reduction in diarrhea duration when S boulardii was given to children within 72 hours after the onset of acute diarrhea.
The present study suggests a complementary treatment of acute diarrhea in infants with daily oral doses of S boulardii.
*Departamento de Pediatria, Faculdade de Medicina
†Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais
‡Departamento de Pediatria e Puericultura, Universidade Federal de Goiás, Goiânia, Goiás, Brazil.
Address correspondence and reprint requests to Jacques R. Nicoli, PhD, Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, 301270-901 Minas Gerais, Brazil (e-mail: email@example.com).
Received 12 January, 2011
Accepted 20 June, 2011
The study was supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Coordenação de Aperfeiçoamento do Pessoal de Ensino Superior (CAPES).
The authors report no conflicts of interest.